- recruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
United States · Canada · China - active not recruitingPHASE2, PHASE3
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
This study is looking at a new drug, Navlimetostat, combined with standard treatment (Nab-paclitaxel and Gemcitabine) for pancreatic cancer that has spread. It's for people whose cancer has a specific genetic change called MTAP deletion, which the new drug targets.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
United States · Australia · Canada - recruitingPHASE1, PHASE2
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This study is testing a new experimental medicine, AZD5863, for people with advanced stomach, oesophageal, or pancreatic cancer. It aims to see if the medicine is safe, what dose works best, and if it can help fight the cancer.
United States · China · France - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1
This study is looking at a new treatment called NP137 when given alongside a common chemotherapy for pancreatic cancer. It's for adults with a type of pancreatic cancer that hasn't spread far but can't be removed by surgery. The aim is to see if these treatments work well together.
France - recruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
United States · Australia · Canada - recruitingPHASE1
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
This study is testing a new medicine for people with advanced cancers that haven't responded to other treatments. It aims to see how safe the medicine is, how it moves through the body, and what dose works best.
United States · Canada - recruitingPHASE1, PHASE2
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is looking at two new medicines, Elironrasib and Daraxonrasib, for people with advanced cancers that have a specific genetic change called KRAS G12C. Researchers want to see if these medicines are safe and how well they work, both alone and together.
United States · France · Germany - recruitingPHASE1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
This study is testing a new drug, ASP5834, for adults with certain solid cancers. It aims to find the right dose and check for side effects, sometimes given with another cancer drug called panitumumab, especially for bowel cancer.
United States · France · Japan - recruitingPHASE2, PHASE3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
This study is looking into a new treatment called SBP-101 for advanced pancreatic cancer. It combines SBP-101 with standard chemotherapy (nab-paclitaxel and gemcitabine) to see if it helps people live longer and improves their quality of life.
United States · Australia · Austria - not yet recruitingPHASE3
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
This study looks at new ways to choose chemotherapy after pancreatic cancer surgery to prevent it from returning. Researchers are comparing standard methods with a new genetic test to see which works best for patients in the UK.
Germany · Sweden - active not recruitingPHASE1
A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer
This study for advanced pancreatic cancer tests a new treatment. It combines an immunotherapy (a protein alongside a virus that may kill cancer cells) with ezabenlimab, a drug that may boost your immune system. The aim is to find safe doses and see if it helps people live longer.
United States · Germany · Spain - authorisedTherapeutic confirmatory (Phase III)
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
This study looks at different ways to give chemotherapy before surgery for pancreatic cancer. We want to see if a shorter or longer course of treatment works better in helping people live longer and preventing the cancer from growing.
Italy - active not recruiting
Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers
This study is looking for better ways to spot pancreatic cancer early. Researchers are collecting urine and blood samples from people with and without pancreatic problems. They hope to find a simple test to help doctors diagnose pancreatic conditions sooner, which could lead to more effective treatment.
United Kingdom - recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain - active not recruitingPHASE1, PHASE2
Study for AZD4360 in Participants With Advanced Solid Tumours
This study is testing a new drug, AZD4360, for people with advanced stomach, bile duct, or pancreatic cancers that have a specific marker called CLDN18.2. It aims to see how safe it is and if it helps shrink tumors.
United States · China · Germany - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination with Anti-cancer Agents in Participants with Tumours Harbouring a KRASG12D Mutation (ALAFOSS-01)
This study looks at a new drug, AZD0022, for people with certain types of lung, bowel, and pancreatic cancer. Doctors want to see if it's safe, how the body handles it, and if it can help shrink tumours, both on its own and with other cancer drugs.
Belgium · Poland · Italy - recruiting
Pancreatic Cancer Early Detection Consortium
This study aims to find better ways to spot pancreatic cancer early, especially in people with a higher risk due to family history or specific genetic changes. Researchers will collect health information and samples over time to understand how the disease develops.
United States · Australia · Canada